Search | Clinical Trials Finder

Conditions: Triple Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 38
States / cities: Mobile, Alabama • Chandler, Arizona • Duarte, California + 32 more

Conditions: Triple Negative Breast Neoplasms
Interventions: Atezolizumab, Placebo, Gemcitabine, Capecitabine, Carboplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Paramus, New Jersey + 3 more

Conditions: Breast Neoplasms
Interventions: Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin, Gemcitabine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Cerritos, California • Long Beach, California + 35 more

Conditions: Breast Cancer
Interventions: Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 27
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 23 more

Conditions: Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
Interventions: Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Therapeutic Estradiol; Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more

Conditions: Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Interventions: A2B395, xT CDx with HLA-LOH assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab; Drug · Other · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • Lake Forest, Illinois

Conditions: Breast Cancer, Metastasis
Interventions: Dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 5
States / cities: San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more

Conditions: Locally Recurrent/Metastatic Triple Negative Breast Cancer
Interventions: external beam radiation therapy, cisplatin, Biopsy of Target Tumor; Radiation · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Triple Negative Breast Cancer
Interventions: No drug; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Breast Cancer Metastatic
Interventions: PF-03084014, Docetaxel; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 11
States / cities: Birmingham, Alabama • Stanford, California • Detroit, Michigan + 1 more

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 63
States / cities: Daphne, Alabama • Springdale, Arkansas • Duarte, California + 54 more

Conditions: Triple-Negative Breast Cancer, Breast Cancer
Interventions: Romidepsin, Cisplatin, Nivolumab; Drug
Lead sponsor: Priyanka Sharma; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 7
States / cities: Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 3 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Breast Cancer, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Triple Negative Breast Cancer
Interventions: Pembrolizumab, Cisplatin; Biological · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions: Not listed
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 18
States / cities: Denver, Colorado • Elizabeth City, North Carolina • Portland, Oregon + 11 more

Conditions: Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 3
States / cities: Hershey, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Breast Cancer, Breast Carcinoma, Breast Tumors, Malignant Neoplasm of Breast
Interventions: Paclitaxel, Alisertib; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Including Dallas and Austin, Texas

Conditions: Breast Neoplasms
Interventions: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 47
States / cities: Springdale, Arkansas • La Jolla, California • Los Angeles, California + 34 more

Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer
Interventions: ATX-295; Drug
Lead sponsor: Accent Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Sarasota, Florida • Nashville, Tennessee • Houston, Texas + 2 more

Conditions: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Interventions: OTS167PO; Drug
Lead sponsor: OncoTherapy Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 8
States / cities: Norwalk, Connecticut • Atlanta, Georgia • Honolulu, Hawaii + 4 more

Conditions: Triple Negative Breast Cancer
Interventions: Tivozanib Hydrochloride, paclitaxel, Placebo; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 17 more

Conditions: Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma
Interventions: NKTR-262, bempegaldesleukin, nivolumab; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Scottsdale, Arizona • La Jolla, California • Tampa, Florida + 11 more

Conditions: Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms
Interventions: Mifepristone and Eribulin in combination; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 11
States / cities: Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Triple Negative Breast Neoplasms
Interventions: Pembrolizumab, Olaparib, Carboplatin, Gemcitabine; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 25
States / cities: Monterey, California • San Francisco, California • Santa Monica, California + 20 more

Search by objective public record fields.

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Triple Negative Breast Cancer Biomarker Study

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)